RDNT · RadNet, Inc.
$69.93
+2.23 (+3.29%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$5.57B
Shares
78.70M
Volume · Oct 2
574.27K
Avg daily vol (3M)
750.69K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$67.70
Open$68.80
Day$67.32–69.70
52W close$51.87–84.48
Avg vol 30d721K
Short int9.7M · 12.3% float · 11.9d
Short vol86%
Last earningsAug 10, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held May 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.27B
Trailing 12 months
Net income (TTM)
−$21.12M
Trailing 12 months
Revenue growth YoY
+25.0%
Year over year
Operating margin
3.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
2.3%
Trailing 12 months
Net cash
−$606.26M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.2%
Year over year · more shares
Price change (1Y)
-13.2%
Trailing year
Short interest
12.3%
Latest settlement · 11.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
−6%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
49%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
+22%
trailing
YTD return
−5%
this year
Relative strength
+10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $72 › 200d $65 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.29% of float · ▼ -2.7% MoM · 11.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
331 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+13%
Y/Y
EPS growth
−725%
Y/Y
Free cash flow
$224.7M
Balance sheet
$558.4M
net debt
Quant / Vol
risk profile
Volatility
42%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
Imaging Center Segment - Revised Guidance Range After Q2 Results
Cash Interest Expense
$48M – $53M
Free Cash Flow
Non-GAAP
$115M – $125M
Digital Health Segment - Revised Guidance Range After Q2 Results
Free Cash Flow Before Non-Capitalized R&D - DeepHealth Cloud OS
Non-GAAP
$-1M – $3M
Guided vs delivered
· last 3 settled
Total net revenue
2023
guided $1.58B – $1.61B
$1.62B
Beat +1.5%
Total net revenue
2022
guided $1.35B – $1.4B
$1.43B
Beat +4.0%
Total net revenue
2021 fiscal year
guided $1.3B – $1.35B
$1.32B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
49%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $72 › 200d $65 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.29% of float · ▼ -2.7% MoM · 11.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
331 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $52
Now $68 · 49%
Range high $84
vs 200-day avg +3%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings non-GAAP | $23.2M | Q2 2026 | — |
| Adjusted Earnings Per Share non-GAAP | $0.29 | Q2 2026 | — |
| Adjusted EBITDA - Digital Health Segment non-GAAP | $3.78M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Imaging Center non-GAAP | $97.18M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA - Imaging Center Segment non-GAAP | $159.14M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Radnet, Inc. non-GAAP | $162.92M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA - Total Company non-GAAP | $99.66M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) attributable to RadNet, Inc. common stockholders 7.53M
+6.36M Income taxes
+18.15M Interest expense
+660K Severance costs
+45.53M Depreciation and amortization
+10.54M Non-cash employee stock-based compensation
+1.12M Loss on sale and disposal of equipment and other
+0K Non-cash change in fair value of interest rate hedge
-3.96M Other income
+5.11M Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI
+1.31M Lease abandonment charges
+3.37M Loss (gain) on extinguishment of debt and related expenses
-3.16M Non-cash change to contingent consideration
+498K Non-operational rent expenses
+6.6M Acquisition transaction costs
= Adjusted EBITDA - Total Company 99.66M
|
|||
| Adjusted EBITDA Margin - Imaging Center Segment non-GAAP | 16.1% | Q2 2026 | — |
| advanced imaging as a percentage of total procedural volumes | 29.9% | Q2 2026 | — |
| aggregate advanced imaging procedural volumes growth | 21.2% | Q2 2026 | — |
| Annual Recurring Revenue (ARR) - Digital Health non-GAAP | $105.5M | Q2 2026 | — |
| balance sheet cash | $726.3M | Q2 2026 | — |
| CT volume growth | 20.9% | Q2 2026 | — |
| joint venture locations | 157 | Q2 2026 | — |
| new business Total Contract Value signed | $21M | Q2 2026 | — |
| owned and operated outpatient imaging centers | 442 | Q2 2026 | — |
| PET/CT volume growth | 31% | Q2 2026 | — |
| Procedures by Modality - CT | 352,734 | Second Quarter 2026 | — |
| Procedures by Modality - Mammography | 537,732 | Second Quarter 2026 | — |
| Procedures by Modality - MRI | 593,143 | Second Quarter 2026 | — |
| Procedures by Modality - Nuclear Medicine | 10,460 | Second Quarter 2026 | — |
| Procedures by Modality - PET/CT | 29,027 | Second Quarter 2026 | — |
| Procedures by Modality - Total | 3,262,013 | Second Quarter 2026 | — |
| Procedures by Modality - Ultrasound | 776,541 | Second Quarter 2026 | — |
| Procedures by Modality - X-ray and Other | 962,376 | Second Quarter 2026 | — |
| routine imaging volume growth | 7.9% | Q2 2026 | — |
| same-center advanced imaging procedural volumes growth | 9.6% | Q2 2026 | — |
| same-center CT volume growth | 8.6% | Q2 2026 | — |
| same-center MRI volume growth | 10.2% | Q2 2026 | — |
| same-center PET/CT volume growth | 8.8% | Q2 2026 | — |
| same-center routine imaging volume growth | 1.7% | Q2 2026 | — |
| Systemwide same center procedural volumes by modality - CT non-GAAP | 315,226 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Mammography non-GAAP | 505,871 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - MR non-GAAP | 537,894 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Nuclear Medicine non-GAAP | 8,442 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - PET/CT non-GAAP | 23,980 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Total non-GAAP | 3,027,879 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - Ultrasound non-GAAP | 723,473 | Three Months Ended June 30, 2026 filing | — |
| Systemwide same center procedural volumes by modality - X-ray and Other non-GAAP | 912,993 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RDNT
this stock
RadNet, Inc.
|
$5.57B | -5.1% | +13.0% | — | 12.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +12.6% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -7.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +78.3% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +22.5% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RDNT | -5.1% | -10.6% | +22.1% | -1.8% | -5.1% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -4.6% | -10.4% | +9.7% | -2.0% | -17.2% |